# DP-R213 Phase 1 Pharmacokinetics Study

> **NCT03010267** · PHASE1 · COMPLETED · sponsor: **Alvogen Korea** · enrollment: 46 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** DP-R213
- **DRUG:** Raloxifene
- **DRUG:** Cholecaliferol

## Key facts

- **NCT ID:** NCT03010267
- **Lead sponsor:** Alvogen Korea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-03
- **Primary completion:** 2017-03-08
- **Final completion:** 2017-03-29
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2017-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03010267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03010267, "DP-R213 Phase 1 Pharmacokinetics Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03010267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*